OncoMatch/Clinical Trials/NCT07795528
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
Is NCT07795528 recruiting? Yes, currently enrolling (Sep 2026).
This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation (KRAS, NRAS, BRAF, or PIK3CA). Serial plasma circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) will be performed with a standardized 10-gene next-generation sequencing (NGS) panel at predefined time points during 3 years of postoperative follow-up. The primary objective is to evaluate the association between postoperative ctDNA-based MRD status and recurrence-free survival (RFS). Secondary objectives include evaluating overall survival (OS), the interval between first MRD detection and radiologically confirmed recurrence, and the association between longitudinal MRD changes and outcomes following adjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: BRAF driver mutation
Required: KRAS driver mutation
Required: NRAS driver mutation
Required: PIK3CA driver mutation
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
no prior anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy) before surgery
Cannot have received: radiation therapy
no prior anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy) before surgery
Cannot have received: targeted therapy
no prior anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy) before surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07795528 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require BRAF?
Yes, BRAF driver mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS driver mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS driver mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify